A detailed history of Bi Asset Management Fondsmaeglerselskab A transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Bi Asset Management Fondsmaeglerselskab A holds 2,170 shares of BMRN stock, worth $143,241. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,170
Previous 5,723 62.08%
Holding current value
$143,241
Previous $500,000 64.2%
% of portfolio
0.0%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$74.43 - $92.22 $264,449 - $327,657
-3,553 Reduced 62.08%
2,170 $179,000
Q1 2024

May 03, 2024

SELL
$83.81 - $99.0 $236,344 - $279,180
-2,820 Reduced 33.01%
5,723 $500,000
Q4 2023

Feb 09, 2024

BUY
$76.22 - $98.51 $414,179 - $535,303
5,434 Added 174.78%
8,543 $824,000
Q2 2023

Aug 03, 2023

BUY
$86.68 - $100.3 $152,470 - $176,427
1,759 Added 130.3%
3,109 $269,000
Q1 2023

May 12, 2023

SELL
$87.74 - $117.27 $398,251 - $532,288
-4,539 Reduced 77.08%
1,350 $131,000
Q4 2022

Feb 13, 2023

BUY
$80.93 - $108.63 $3,884 - $5,214
48 Added 0.82%
5,889 $609,000
Q3 2022

Nov 07, 2022

BUY
$82.16 - $96.94 $78,134 - $92,189
951 Added 19.45%
5,841 $495,000
Q1 2022

May 11, 2022

BUY
$74.28 - $92.69 $363,229 - $453,254
4,890 New
4,890 $377,000
Q4 2020

Feb 12, 2021

SELL
$72.61 - $90.2 $66,583 - $82,713
-917 Closed
0 $0
Q3 2020

Nov 09, 2020

BUY
$71.87 - $131.03 $65,904 - $120,154
917 New
917 $70,000
Q1 2020

May 11, 2020

SELL
$71.37 - $96.85 $110,694 - $150,214
-1,551 Closed
0 $0
Q4 2019

Mar 19, 2020

SELL
$64.27 - $86.37 $192,424 - $258,591
-2,994 Reduced 65.87%
1,551 $131,000
Q3 2019

Mar 19, 2020

BUY
$67.4 - $85.11 $70,230 - $88,684
1,042 Added 29.75%
4,545 $306,000
Q2 2019

Mar 19, 2020

BUY
$80.35 - $93.9 $281,466 - $328,931
3,503 New
3,503 $300,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.3B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Bi Asset Management Fondsmaeglerselskab A Portfolio

Follow Bi Asset Management Fondsmaeglerselskab A and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bi Asset Management Fondsmaeglerselskab A, based on Form 13F filings with the SEC.

News

Stay updated on Bi Asset Management Fondsmaeglerselskab A with notifications on news.